Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 7c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $4.18 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Lakeland Bancorp (LBAI) Tops Q1 EPS by 1c